Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers.

ABSTRACT:

Background and objective

Gestational diabetes mellitus (GDM) "programs" an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplementation in GDM affects neonatal metabolic health biomarkers especially leptin and adiponectin.

Methods

In a randomized controlled trial, singleton pregnant women with de novo diagnosis of GDM at 24-28  weeks of gestation were randomized to dietary supplementation of 500 mg DHA per day (intervention, n = 30) until delivery or standard care (control, n = 38). The primary outcomes were cord blood leptin and total adiponectin concentrations. Secondary outcomes inc

SUBMITTER: Xu YJ 

PROVIDER: S-EPMC10069675 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature